EUCTR2015-004472-30-ES进行中（未招募）1 期
Randomized phase III trial on Trabectedin (ET-743) vs clinician's choicechemotherapy in recurrent ovarian, primary peritoneal or fallopian tubecancers of BRCA mutated or BRCAness phenotype patientsMITO-23
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 246
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Inclusion criteria
- •1. Female of age 18 years or older
- •2. Histologically or cytologically documented invasive epithelial ovarian
- •cancer, primary peritoneal carcinoma, or fallopian tube cancer
- •3. Platinum resistant or sensitive patients with either:
- •a. BRCA mutated patients
- •b. BRCAness phenotype patients: patients who have received and
- •responded (subsequent PFI>6 months) to at least 2 previous platinum
- •based chemotherapy lines
- •c. Platinum sensitive patients who are not able to receive or not willing
- •to receive other platinum treatments
- •4. Measurable and evaluable disease per RECIST 1.1(Subjects with
- •isolated rising CA-125 without radiologically visible disease are
- •5. ECOG performance status 0 or 1
- •6. No limits in the number of previous chemotherapy lines, previous
- •treatment with parp inhibitors is allowed
- •7. Left Ventricular Ejection Fraction (LVEF) = institutional lower limit
- •8. Life expectancy of at least 3 months
- •9. Adequate organ functions:
- •a. Hematopoietic: Absolute neutrophil count = 1,500/mm3;
- •Platelet count = 100,000/mm3; Hemoglobin = 9 g/dl
- •b. Hepatic: AST and ALT = 1.5 times upper limit of normal
- •(ULN)* ; Alkaline Phosphatase = 2.5 times ULN* ; Bilirubin = 1.5 times
- •ULN. NOTE: * = 3 times ULN if liver metastases are present
- •c. Renal: Creatinine Clearance = 45 ml/min or Serum Creatinine =1.5 x
- •d. Serum Albumin >2.5 g/dl
- •10. No other invasive malignancy within the past 3 years except nonmelanoma
- •skin cancer or in situ cervical cancer (patients with previous
- •cancers may be enrolled providing that no recurrences have be reported
- •in the last 3 years)
- •11. Written Informed Consent
- •12. Adequately recovered from the acute toxicity of any prior treatment
- •13. For agents in the standard arm, also refer to the local prescribing
- •information
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 44
排除标准
- •Exclusion criteria
- •1. Prior exposure to trabectedin
- •2. Known hypersensitivity to any of the components of the trabectedin
- •i.v. formulation or dexamethasone
- •3. Subjects with borderline ovarian cancer, ie. Subject with low
- •malignant potential tumors are excluded
- •4. At least 2 reported responses to platinum (i.e. subsequent recurrences
- •at least 6 months after the first and the second platinum based
- •treatment), unless BRCA mutation is documented.
- •5. Less than 4 weeks from last dose of therapy with any investigational
- •agent, or chemotherapy
- •6. History of another neoplastic disease (except basal cell carcinoma or
- •cervical carcinoma in situ adequately treated) unless in remission for 3
- •years or longer
- •7. Known clinically relevant CNS metastases, unless treated and
- •asymptomatic
- •8. Other serious illnesses, such as:
- •a. Congestive heart failure or angina pectoris; myocardial infarction
- •within 1 year before enrolment; uncontrolled arterial hypertension or
- •arrhythmias.
- •b. Psychiatric disorder that prevents compliance with protocol.
- •c. Active viral hepatitis; or chronic liver disease.
- •d. Active infection.
- •e. Any other unstable medical conditions.
研究者
相似试验
进行中（未招募）
1 期
overall survival of patients with recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype treated with trabectedin compared to a standard treatmentEUCTR2015-004472-30-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI244
已完成
3 期
Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype PatientsOvarian NeoplasmsNCT02903004Fondazione Policlinico Universitario Agostino Gemelli IRCCS242
已完成
3 期
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)SarcomaNCT00796120Johnson & Johnson Pharmaceutical Research & Development, L.L.C.121
已完成
2 期
ET 743 (Yondelis) in Men With Advanced Prostate CancerProstate CancerNCT00147212Massachusetts General Hospital50
进行中（未招募）
1 期
combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugsplatinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneumMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2018-000230-35-ITFONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS66